Triple-Target Incretin Drug Kills Knee Osteoarthritis Pain in Obesity

Knee osteoarthritis pain relief – and massive weight loss – from new GLP-1

Two Phase 3 clinical trials that involved more than 1,000 adults have significantly strengthened the case for Eli Lilly's experimental GLP-1-based drug retatrutide to gain FDA approval for both weight loss and relief from knee osteoarthritis (OA).Continue ReadingCategory: Obesity, Illnesses and conditions, Body and MindTags: GLP-1 receptor agonists, Weight Loss, clinical trials, Experimental, Drug development, Arthritis, Healthy aging, Obesity, …

Triple-Target Incretin Drug Kills Knee Osteoarthritis Pain in Obesity

(MedPage Today) -- ORLANDO -- The investigational obesity drug retatrutide was highly effective in reducing pain and improving disability in knee osteoarthritis (OA) associated with obesity, according to the TRIUMPH-4 trial. Among patients in...

Experimental weight-loss drug eases painful knee osteoarthritis in two clinical trials

Experimental weight-loss drug eases painful knee osteoarthritis in two clinical trials For people with painful knee osteoarthritis (OA) who are overweight or have obesity, everyday activities such as walking, climbing stairs and standing up from a chair can be difficult. In two Northwestern…